Lisata Therapeutics, Inc.

Welcome to the Lissata Therapeutics second quarter 2023 financial results and business update conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star 1 1 on your telephone. You will then hear an automated message advising you your hand is raised. As a reminder, the call is being recorded today. Tuesday, August 15, 2023. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications at Lasada. Please go ahead, sir.

Thank you, Operator, and good morning, everyone. Welcome to Lasada's second quarter 2023 conference call to discuss our financial results and the opportunity to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer, Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Financial Officer, and James Nisko, Vice President of Finance and Treasury. Yesterday, Monday, August 14th, we issued a press release after market trading closed, announcing our second quarter 2023 financial results, which is available under the investors and news section of the company website, along with the webcast replay of this call. If you have not received the news release or if you'd like to be added to the company's email distribution list, please email me at jmendito at lisata.com. Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of LISATA. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitations, It forms 10Q, 8K, and 10K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Tuesday, August 15, 2023. FASADA undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that, I'll now turn the call over to Dr. Mazzo. Dave?

Thank you, John, and good morning, everyone. Thank you for joining us today as we provide an overview of recent business highlights, discuss our second quarter 2023 financial results, and give an update on the progress of our various development programs. I'm kicking off today's call with a heightened sense of excitement and optimism for the future of Lesado. During the second quarter, we continued the advancement of our clinical development programs for the treatment of advanced solid tumors. As those familiar with the company know, Lasada is a clinical stage pharmaceutical company focused on the development of a novel solid tumor targeting and penetration technology to improve the efficacy of anti-cancer drugs. Our development portfolio contains programs that are designed to bring significant therapeutic improvement in the treatment of solid tumors in a pharmaco-economically attractive paradigm. Lista-1, our lead product candidate, is the subject of multiple planned and ongoing clinical trials being conducted globally in a variety of solid tumor types and in combination with multiple anti-cancer agents of differing modalities. Based on substantial preclinical and, most importantly, early clinical data in humans, we believe that ListaOne has the potential to become an integral part of a revised standard of care treatment regimen for many difficult to treat cancers. During this call, our chief medical officer, Dr. Kristen Buck, will provide more specifics on our clinical programs following our review of financial results. However, before moving on to the financial and clinical overview, we are pleased to announce a significant milestone in the form of a technology transfer agreement of our tumor-penetrating nanocomplex, or TPN, platform with Impilo Therapeutics, Inc., a recently formed company led by David Slatt, former LASADA chief business officer. The TPN platform targets intracellular delivery of RNA-based drugs to prevent solid tumor growth. TPN is designed so that it not only binds to proteins overexpressed on the surface of human cancer cells, but also passes through the membranes by way of a cell-penetrating peptide. Once inside the cells, the TPN is expected to release an RNA-based drug directed against the tumor. The noted technology transfer will place the TPN technology in the capable hands of a team with profound expertise in RNA-based therapeutics development, further enhancing its potential impact in the field. Under the terms of the technology transfer agreement, upon closing, LASADA will receive an equity stake in Impilo Therapeutics. Lestada will also receive a seat on MPILO's Board of Directors, but is not obliged to commit any capital or additional resources to the program's future development. With that, I now will turn the call over to James Nisko, our Vice President of Finance and Treasury, to review and provide commentary on our financial results. James?